Sage Journals: Discover world-class research

Abstract

Background

It has been shown that fluoroquinolones (FQs) use may be associated with an increased risk of aortic aneurysm (AA) and/or aortic dissection (AD).

Objectives

The aim of this meta-analysis was to systematically review and summarize the epidemiological evidence on the risk of aortic AA and/or AD following FQs use.

Design

Systematic review and meta-analysis.

Data Sources and Methods

We performed a meta-analysis using data from PubMed, Embase, and the Cochrane Library, with research conducted up to March 15, 2025. Cohort studies examining the association between FQs use and AA or AD were included. The quality of the included studies was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS). A combined HR with 95% CI was calculated using either a random-effects or fixed-effects model, and robustness was assessed using sensitivity analysis. This meta-analysis was registered with PROSPERO (CRD 420251012072).

Results

11 studies were included, with 81,976,958 participants. The risk of AA/AD among FQs users was found to be elevated (HR = 1.20, 95% CI: 1.06–1.35). Similar results were found for AA (HR = 1.47, 95% CI: 1.24–1.73) and AD (HR = 1.12, 95% CI: 1.04–1.22). In subgroup analysis, the gender subgroup analysis revealed a higher risk of AA/AD for males (HR = 1.16, 95% CI: 1.06–1.27) compared to females (HR = 1.09, 95% CI: 1.00–1.20). Regionally, the risk was higher in America (HR = 1.47, 95% CI: 1.12–1.93) than Europe (HR = 1.08, 95% CI: 0.98–1.19) and Asia (HR = 0.80, 95% CI: 0.61–1.05). Risk associated with FQs use within 90 days (HR = 1.20, 95% CI: 1.13–1.26) was significantly higher, while no significant increase was observed for ≥365 days (HR = 1.00, 95% CI: 0.90–1.12). The presence of hypertension (HR = 1.24, 95% CI: 1.14–1.36) was associated with a significantly higher risk of AA/AD.

Conclusion

This meta-analysis demonstrates that the use of FQs is associated with a significant risk of AA/AD. Clinicians should be aware of this risk in patients prescribed FQs, and further research is needed to elucidate the role of FQs in the development of AA/AD.

Keywords

Fluoroquinolones aortic aneurysm aortic dissection meta-analysis

Get full access to this article

View all access options for this article.

References

Majalekar

Shirote

. Fluoroquinolones: blessings or curses. Curr Drug Targets 2020; 21: 1354–1370.

Baggio

Ananda-Rajah

. Fluoroquinolone antibiotics and adverse events. Aust Prescr 2021; 44: 161–164.

Bennett

Champigneulle

Bennett

, et al. Fluoroquinolone-Associated disability and other fluoroquinolone-associated serious adverse events: unexpected toxicities have emerged in recent years. Cancer Treat Res 2022; 184: 1–39.

Algaidi

Alghamdi

Algheffari

, et al. Long-term cardiovascular adverse events induced by fluoroquinolones: a retrospective case-control Study. J Cardiovasc Pharmacol 2023; 82: 400–406.

Tandan

Cormican

Vellinga

. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2018; 52: 529–540.

Ogino

Iida

Akutsu

, et al. JCS/JSCVS/JATS/JSVS 2020 Guideline on diagnosis and treatment of aortic aneurysm and aortic dissection. Circ J : Official Journal of the Japanese Circulation Society 2023; 87: 1410–1621.

Hou

Zhang

, et al. The burden of aortic aneurysm in China from 1990 to 2019: findings from the Global Burden of Disease Study 2019. BMC Public Health 2022; 22: 782.

Lieberg

Pruks

Kals

, et al. Mortality after elective and ruptured abdominal aortic Aneurysm surgical repair: 12-Year single-center experience of Estonia. Scand J Surg : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 2018; 107: 152–157.

Zhao

Wang

. Biomarkers in aortic dissection: diagnostic and prognostic value from clinical research. Chinese medical journal 2024; 137: 257–269.

10.

Xuan

Cao

, et al. Fluoroquinolones increase susceptibility to aortic aneurysm and aortic dissection: molecular mechanism and clinical evidence. Vasc Med 2023; 28: 604–613.

11.

Dong

Chang

Wang

, et al. Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med 2020; 180: 1587–1595.

12.

Aspinall

Sylvain

Zhao

, et al. Serious cardiovascular adverse events with fluoroquinolones versus other antibiotics: a self-controlled case series analysis. Pharmacology research & perspectives 2020; 8: e00664.

13.

Page

Moher

Bossuyt

, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical research ed) 2021; 372(03/31): n160.

14.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology 2010; 25: 603–605.

15.

Daneman

Redelmeier

. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open 2015; 5: e010077.

16.

Pasternak

Inghammar

Svanström

. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ (Clinical research ed) 2018; 360: k678.

17.

Chen

Yang

Yeh

, et al. Association between aortic aneurysm and aortic dissection with fluoroquinolones use in patients with urinary tract infections: a population-based cohort Study. J Am Heart Assoc 2022; 11: e023267.

18.

Garg

Venugopalan

Vouri

, et al. Oral fluoroquinolones and risk of aortic aneurysm or dissection: a nationwide population-based propensity score-matched cohort study. Pharmacotherapy 2023; 43: 883–893.

19.

Janetzki

Kim

Minty

, et al. Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study. eClinicalMedicine 2025; 81: 103096.

20.

Wicherski

Peltner

Becker

, et al. High risk for life-threatening adverse events of fluoroquinolones in young adults: a large German population-based cohort study. BMC Med 2025; 23: 76.

21.

Brown

Wing

Leyrat

, et al. Association between fluoroquinolone use and hospitalization with aortic aneurysm or aortic dissection. JAMA Cardiol 2023; 8: 865–870.

22.

Gopalakrishnan

Bykov

Fischer

, et al. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med 2020; 180: 1596–1605.

23.

Newton

Akerman

Strassle

, et al. Association of fluoroquinolone use with short-term risk of development of aortic aneurysm. JAMA Surg 2021; 156: 264–272.

24.

Huh

Kang

Jung

. Lack of association between fluoroquinolone and aortic aneurysm or dissection. Eur Heart J 2023; 44: 4476–4484.

25.

Mitrani-Gold

Drysdale

, et al. Risk of collagen-related disorders and neurological events among patients with uncomplicated urinary tract infection following short treatment with fluoroquinolones: a cohort study. Antimicrobial agents and chemotherapy 2024; 68: e0069024.

26.

Chen

Patterson

Simpson

, et al. Do fluoroquinolones increase aortic aneurysm or dissection incidence and mortality? A systematic review and meta-analysis. Frontiers in cardiovascular medicine 2022; 9: 949538.

27.

Jiang

Wang

, et al. Fluoroquinolone use and the risk of collagen-associated adverse events: a systematic review and meta-analysis. Drug Saf 2019; 42: 1025–1033.

28.

Vouga Ribeiro

Gouveia Melo

Guerra

, et al. Fluoroquinolones are associated with increased risk of aortic aneurysm or dissection: systematic review and meta-analysis. Semin Thorac Cardiovasc Surg 2021; 33: 907–918.

29.

Lai

Wang

Chen

, et al. The Association between the risk of aortic Aneurysm/Aortic dissection and the use of fluroquinolones: a systematic review and meta-analysis. Antibiotics (Basel, Switzerland) 2021; 10: 697.

30.

Badal

Her

Maher

3rd . Nonantibiotic effects of fluoroquinolones in Mammalian cells. J Biol Chem 2015; 290: 22287–22297.

31.

Zeng

Liang

Huang

, et al. Ciprofloxacin accelerates Angiotensin-II-Induced vascular smooth muscle cells senescence through modulating AMPK/ROS pathway in aortic aneurysm and dissection. Cardiovasc Toxicol 2024; 24: 889–903.

32.

Xiang

Abudupataer

Liu

, et al. Ciprofloxacin exacerbates dysfunction of smooth muscle cells in a microphysiological model of thoracic aortic aneurysm. JCI Insight 2023; 8: e161729.

33.

Guzzardi

Teng

Kang

, et al. Induction of human aortic myofibroblast-mediated extracellular matrix dysregulation: a potential mechanism of fluoroquinolone-associated aortopathy. J Thorac Cardiovasc Surg 2019; 157: 109–119.

34.

Corps

Harrall

Curry

, et al. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum 2002; 46: 3034–3040.

35.

Cignarella

Bolego

Barton

. Sex and sex steroids as determinants of cardiovascular risk. Steroids 2024; 206: 109423.

36.

GBD 2021 ASEAN Tobacco Collaborators . The epidemiology and burden of smoking in countries of the Association of Southeast Asian Nations (ASEAN), 1990-2021: findings from the Global Burden of Disease Study 2021. Lancet Public Health 2025; 10(6): e442–e455.

37.

Ilhan

Yapar

. Alcohol consumption and alcohol policy. Turk J Med Sci 2020; 50(5): 1197–1202.

38.

Huang

Schaff

Dearani

, et al. A population-based Study of the incidence and natural history of degenerative thoracic aortic aneurysms. Mayo Clin Proc 2021; 96: 2628–2638.

39.

Stackelberg

Björck

Larsson

, et al. Alcohol consumption, specific alcoholic beverages, and abdominal aortic aneurysm. Circulation 2014; 130: 646–652.

40.

Yin

Liu

Wang

, et al. Aortic dissection: global epidemiology. Cardiology 2022; 7(4): 151–161.

Risk of aortic aneurysm/aortic dissection associated with fluoroquinolones use: A meta-analysis of cohort studies

Abstract

Background

Objectives

Design

Data Sources and Methods

Results

Conclusion

Keywords

Get full access to this article

References